Question to the Department of Health and Social Care:

To ask the Secretary of State for Health and Social Care, what assessment he has made of the potential implications for his policies of shortages of ADHD medication.

As a result of intensive work, some issues with attention deficit hyperactivity disorder (ADHD) medicines have resolved. All strengths of lisdexamfetamine, atomoxetine capsules, atomoxetine oral solution and guanfacine prolonged-release tablets are now available.

However, whilst supply of methylphenidate prolonged-release tablets has improved, issues persist. We are continuing to work to resolve these remaining issues by engaging with all suppliers of methylphenidate prolonged-release tablets to assess the challenges faced and their actions to address them. We are also directing suppliers to secure additional stocks, expedite deliveries where possible, and review plans to build further capacity to support continued growth in demand for the short and long-term. The Department is also working with new suppliers of methylphenidate prolonged-release tablets to improve supply and resiliency for the United Kingdom market.

We are supporting an ADHD taskforce established by NHS England to examine ADHD service provision. The taskforce will bring together expertise from across a broad range of sectors, including the National Health Service, education and justice, to help provide a joined-up approach in response to concerns around rising demand. In collaboration with NHS England’s national ADHD data improvement plan, we plan to combine modelling for future growth forecasts, which will be shared with industry to improve demand forecasting for ADHD medicines.

The Department has worked with NHS specialists to develop advice on prescribing alternative ADHD medications. We expect that ADHD service providers should follow this guidance and offer rapid responses for urgent advice, especially for high-risk patients. To aid decision-making at the point of prescribing and dispensing of ADHD medicines, we continue to update a list of available ADHD products on the Specialist Pharmacy Service website.